Analyst Reni Benjamin from JMP Securities reiterated a Buy rating on Prelude Therapeutics (PRLD – Research Report) and keeping the price ...
MyChesCo on MSN15d
Prelude Therapeutics Shares Promising Phase 1 Trial Data for PRT3789 at International SymposiumPrelude Therapeutics Incorporated (Nasdaq: PRLD) has unveiled encouraging results from its ongoing Phase 1 trial of PRT3789, ...
On Thursday, Prelude Therapeutics Inc (PRLD) stock saw a decline, ending the day at $1.2 which represents a decrease of $-0.12 or -9.09% from the prior close of $1.32. The stock opened at $1.31 and ...
In a report released today, Peter Lawson from Barclays maintained a Sell rating on Prelude Therapeutics (PRLD – Research Report), with a price target of $1.00. The company’s shares closed yesterday ...
– Interim data from ongoing trial of PRT3789 showed additional clinical activity at higher doses in patients with non-small cell lung cancer (NSCLC) – First safety data presented from ...
Barclays analyst Peter Lawson lowered the firm’s price target on Prelude Therapeutics (PRLD) to $1 from $3 and keeps an Underweight rating on the shares. The updated SMARCA2 degrader data show ...
Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) ‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and ...
– Interim data from ongoing trial of PRT3789 showed additional clinical activity at higher doses in patients with non-small cell lung cancer (NSCLC) – First safety data presented from ...
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session presentation: October 24, 2024, 10:00 AM CEST (4:00 AM EST ...
Morgan Stanley analyst Jeffrey Hung maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) today and set a price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback